These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 31969562)

  • 1. Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer.
    Ma J; Ramachandran M; Jin C; Quijano-Rubio C; Martikainen M; Yu D; Essand M
    Cell Death Dis; 2020 Jan; 11(1):48. PubMed ID: 31969562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
    Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
    J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Autophagy in Oncolytic Adenoviral Therapy for Cancer.
    Tazawa H; Kuroda S; Hasei J; Kagawa S; Fujiwara T
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28698504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response.
    Wu YY; Sun TK; Chen MS; Munir M; Liu HJ
    Front Cell Infect Microbiol; 2023; 13():1142172. PubMed ID: 37009515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo.
    Xu Q; Rangaswamy US; Wang W; Robbins SH; Harper J; Jin H; Cheng X
    Int J Cancer; 2020 Jan; 146(2):531-541. PubMed ID: 31584185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant viruses delivering the necroptosis mediator MLKL induce a potent antitumor immunity in mice.
    Van Hoecke L; Riederer S; Saelens X; Sutter G; Rojas JJ
    Oncoimmunology; 2020 Aug; 9(1):1802968. PubMed ID: 32923163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1
    Kalus P; De Munck J; Vanbellingen S; Carreer L; Laeremans T; Broos K; Dufait I; Schwarze JK; Van Riet I; Neyns B; Breckpot K; Aerts JL
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic body radiation combined with oncolytic vaccinia virus induces potent anti-tumor effect by triggering tumor cell necroptosis and DAMPs.
    Chen WY; Chen YL; Lin HW; Chang CF; Huang BS; Sun WZ; Cheng WF
    Cancer Lett; 2021 Dec; 523():149-161. PubMed ID: 34606928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy.
    Zhang YQ; Tsai YC; Monie A; Wu TC; Hung CF
    Mol Ther; 2010 Apr; 18(4):692-9. PubMed ID: 20087318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenic cell death in cancer therapy: Present and emerging inducers.
    Zhou J; Wang G; Chen Y; Wang H; Hua Y; Cai Z
    J Cell Mol Med; 2019 Aug; 23(8):4854-4865. PubMed ID: 31210425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined p14ARF and Interferon-β Gene Transfer to the Human Melanoma Cell Line SK-MEL-147 Promotes Oncolysis and Immune Activation.
    Cerqueira OLD; Clavijo-Salomon MA; Cardoso EC; Citrangulo Tortelli Junior T; Mendonça SA; Barbuto JAM; Strauss BE
    Front Immunol; 2020; 11():576658. PubMed ID: 33193370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.
    Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A
    J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity.
    Greiner S; Humrich JY; Thuman P; Sauter B; Schuler G; Jenne L
    Clin Exp Immunol; 2006 Nov; 146(2):344-53. PubMed ID: 17034588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crosstalk between oncolytic viruses and autophagy in cancer therapy.
    Jin KT; Tao XH; Fan YB; Wang SB
    Biomed Pharmacother; 2021 Feb; 134():110932. PubMed ID: 33370632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic adenovirus ORCA-010 increases the type 1 T cell stimulatory capacity of melanoma-conditioned dendritic cells.
    López González M; van de Ven R; de Haan H; van Eck van der Sluijs J; Dong W; van Beusechem VW; de Gruijl TD
    Clin Exp Immunol; 2020 Aug; 201(2):145-160. PubMed ID: 32301504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses.
    Garg AD; Agostinis P
    Immunol Rev; 2017 Nov; 280(1):126-148. PubMed ID: 29027218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis.
    Tazawa H; Kagawa S; Fujiwara T
    Acta Med Okayama; 2013; 67(6):333-42. PubMed ID: 24356717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Functional Assay to Determine the Capacity of Oncolytic Viruses to Induce Immunogenic Tumor Cell Death.
    Delaunay T; Achard C; Grégoire M; Tangy F; Boisgerault N; Fonteneau JF
    Methods Mol Biol; 2020; 2058():127-132. PubMed ID: 31486035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.